Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
| ▸ | GYS1 | P13807 | 1/20 | 0.41 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.39 |
| ▸ | CASP6 | P55212 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12852614 | 0.87 | ACACB (0.46) | ACACBHDAC6MEN1KMT2APDK2 | |
| SCHEMBL13151159 | 0.85 | ACACB (0.46) | ACACBHDAC6MEN1KMT2APDK2 | |
| SCHEMBL20888484 | 0.83 | HPGD (0.50) | MEN1KMT2AALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL20888459 | 0.81 | HTT (0.44) | MEN1KMT2ATDP1HTTNPC1 | |
| SCHEMBL19903834 | 0.78 | HPGD (0.58) | ACACBHDAC6MEN1KMT2APDK2 | |
| SCHEMBL23471148 | 0.78 | CYP4F2 (0.55) | ACACBMEN1KMT2APDK2ALDH1A1 | |
| SCHEMBL20888517 | 0.77 | HTT (0.44) | MEN1KMT2AALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL1196682 | 0.77 | MEN1 (0.47) | ACACBHDAC6MEN1KMT2APDK2 | |
| SCHEMBL21413678 | 0.77 | CDK4 (0.56) | ACACBHDAC6MEN1KMT2APDK2 | |
| SCHEMBL3646900 | 0.77 | MEN1 (0.51) | ACACBMEN1KMT2APDK2SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024305-A1 | METHODS AND COMPOSITIONS FOR TREATING RETINA-ASSOCIATED DISEASE USING CCR3-INHIBITORS | ALKAHEST, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11590118-B2 | Methods and compositions for treating retina-associated disease using CCR3-inhibitors | ALKAHEST INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-11382907-B2 | Methods and compositions for treating aging-associated impairments using CCR3-inhibitors | ALKAHEST, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210106577-A1 | METHODS AND COMPOSITIONS FOR TREATING RETINA-ASSOCIATED DISEASE USING CCR3-INHIBITORS | ALKAHEST, INC. | 2021-04-15 | — | — | US | disclosed |
| US-20190105314-A1 | Methods and Compositions for Treating Aging-Associated Impairments Using CCR3-Inhibitors | ALKAHEST, INC. | 2019-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190105314-A1 | Methods and Compositions for Treating Aging-Associated Impairments Using CCR3-Inhibitors | CCR3, CCR1, CCR4 | ACACB 2554/4885HDAC6 317/4885MEN1 2820/4885 |
| US-20210106577-A1 | METHODS AND COMPOSITIONS FOR TREATING RETINA-ASSOCIATED DISEASE USING CCR3-INHIBITORS | CCR3, CCR1, CCR4 | ACACB 2626/4885HDAC6 1347/4885MEN1 4450/4885 |
| US-20240024305-A1 | METHODS AND COMPOSITIONS FOR TREATING RETINA-ASSOCIATED DISEASE USING CCR3-INHIBITORS | CCR3, CCR1, CCR4 | ACACB 2626/4885HDAC6 1347/4885MEN1 4450/4885 |
| US-11590118-B2 | Methods and compositions for treating retina-associated disease using CCR3-inhibitors | CCR3, CCR1, CCR4 | ACACB 2626/4885HDAC6 1347/4885MEN1 4450/4885 |
| US-11382907-B2 | Methods and compositions for treating aging-associated impairments using CCR3-inhibitors | CCR3, CCR1, CCR4 | ACACB 2554/4885HDAC6 317/4885MEN1 2820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.